Your browser doesn't support javascript.
loading
Hepatocyte-specific activity of TSC22D4 triggers progressive NAFLD by impairing mitochondrial function.
Wolff, Gretchen; Sakurai, Minako; Mhamane, Amit; Troullinaki, Maria; Maida, Adriano; Deligiannis, Ioannis K; Yin, Kelvin; Weber, Peter; Morgenstern, Jakob; Wieder, Annika; Kwon, Yun; Sekar, Revathi; Zeigerer, Anja; Roden, Michael; Blüher, Matthias; Volk, Nadine; Poth, Tanja; Hackert, Thilo; Wiedmann, Lena; De Angelis Rigotti, Francesca; Rodriguez-Vita, Juan; Fischer, Andreas; Mukthavaram, Rajesh; Limphong, Pattraranee; Tachikawa, Kiyoshi; Karmali, Priya; Payne, Joseph; Chivukula, Padmanabh; Ekim-Üstünel, Bilgen; Martinez-Jimenez, Celia P; Szendrödi, Julia; Nawroth, Peter; Herzig, Stephan.
Affiliation
  • Wolff G; Institute for Diabetes and Cancer (IDC), Helmholtz Diabetes Center, Helmholtz Centre Munich, Neuherberg, Germany; Joint Heidelberg-IDC Translational Diabetes Program, Inner Medicine 1, Heidelberg University Hospital, Heidelberg, Germany; German Center for Diabetes Research (DZD), Neuherberg, Germany
  • Sakurai M; Institute for Diabetes and Cancer (IDC), Helmholtz Diabetes Center, Helmholtz Centre Munich, Neuherberg, Germany; Joint Heidelberg-IDC Translational Diabetes Program, Inner Medicine 1, Heidelberg University Hospital, Heidelberg, Germany; German Center for Diabetes Research (DZD), Neuherberg, Germany
  • Mhamane A; Institute for Diabetes and Cancer (IDC), Helmholtz Diabetes Center, Helmholtz Centre Munich, Neuherberg, Germany; Joint Heidelberg-IDC Translational Diabetes Program, Inner Medicine 1, Heidelberg University Hospital, Heidelberg, Germany; German Center for Diabetes Research (DZD), Neuherberg, Germany
  • Troullinaki M; Institute for Diabetes and Cancer (IDC), Helmholtz Diabetes Center, Helmholtz Centre Munich, Neuherberg, Germany; Joint Heidelberg-IDC Translational Diabetes Program, Inner Medicine 1, Heidelberg University Hospital, Heidelberg, Germany; German Center for Diabetes Research (DZD), Neuherberg, Germany
  • Maida A; Institute for Diabetes and Cancer (IDC), Helmholtz Diabetes Center, Helmholtz Centre Munich, Neuherberg, Germany; Joint Heidelberg-IDC Translational Diabetes Program, Inner Medicine 1, Heidelberg University Hospital, Heidelberg, Germany; German Center for Diabetes Research (DZD), Neuherberg, Germany
  • Deligiannis IK; Helmholtz Pioneer Campus (HPC), Helmholtz Zentrum München, Neuherberg, Germany.
  • Yin K; Helmholtz Pioneer Campus (HPC), Helmholtz Zentrum München, Neuherberg, Germany; University of Cambridge, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, United Kingdom.
  • Weber P; Institute for Diabetes and Cancer (IDC), Helmholtz Diabetes Center, Helmholtz Centre Munich, Neuherberg, Germany; Joint Heidelberg-IDC Translational Diabetes Program, Inner Medicine 1, Heidelberg University Hospital, Heidelberg, Germany; German Center for Diabetes Research (DZD), Neuherberg, Germany
  • Morgenstern J; Institute for Diabetes and Cancer (IDC), Helmholtz Diabetes Center, Helmholtz Centre Munich, Neuherberg, Germany; Joint Heidelberg-IDC Translational Diabetes Program, Inner Medicine 1, Heidelberg University Hospital, Heidelberg, Germany; German Center for Diabetes Research (DZD), Neuherberg, Germany
  • Wieder A; Institute for Diabetes and Cancer (IDC), Helmholtz Diabetes Center, Helmholtz Centre Munich, Neuherberg, Germany; Joint Heidelberg-IDC Translational Diabetes Program, Inner Medicine 1, Heidelberg University Hospital, Heidelberg, Germany; German Center for Diabetes Research (DZD), Neuherberg, Germany
  • Kwon Y; Institute for Diabetes and Cancer (IDC), Helmholtz Diabetes Center, Helmholtz Centre Munich, Neuherberg, Germany; Joint Heidelberg-IDC Translational Diabetes Program, Inner Medicine 1, Heidelberg University Hospital, Heidelberg, Germany; German Center for Diabetes Research (DZD), Neuherberg, Germany
  • Sekar R; Institute for Diabetes and Cancer (IDC), Helmholtz Diabetes Center, Helmholtz Centre Munich, Neuherberg, Germany; Joint Heidelberg-IDC Translational Diabetes Program, Inner Medicine 1, Heidelberg University Hospital, Heidelberg, Germany; German Center for Diabetes Research (DZD), Neuherberg, Germany
  • Zeigerer A; Institute for Diabetes and Cancer (IDC), Helmholtz Diabetes Center, Helmholtz Centre Munich, Neuherberg, Germany; Joint Heidelberg-IDC Translational Diabetes Program, Inner Medicine 1, Heidelberg University Hospital, Heidelberg, Germany; German Center for Diabetes Research (DZD), Neuherberg, Germany
  • Roden M; Division of Endocrinology and Diabetology, Medical Faculty, Heinrich Heine University, Dusseldorf, Germany; Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Dusseldorf, Germany.
  • Blüher M; Helmholtz Institute for Metabolic, Obesity and Vascular Research (HI-MAG), Helmholtz Zentrum München, Germany; Medical Department III - Endocrinology, Nephrology, Rheumatology, University of Leipzig Medical Center, University of Leipzig, Germany.
  • Volk N; Tissue Bank of the National Center for Tumor Diseases (NCT) Heidelberg, Germany; Institute of Pathology, Heidelberg University Hospital, Germany.
  • Poth T; CMCP - Center for Model System and Comparative Pathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
  • Hackert T; Department of General, Visceral and Transplant Surgery, Heidelberg University Hospital, Heidelberg, Germany.
  • Wiedmann L; Division Vascular Signaling and Cancer (A270), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • De Angelis Rigotti F; Division Vascular Signaling and Cancer (A270), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Rodriguez-Vita J; Division Vascular Signaling and Cancer (A270), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Fischer A; Division Vascular Signaling and Cancer (A270), German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Endocrinology and Clinical Chemistry, Heidelberg University Hospital, Heidelberg, Germany.
  • Mukthavaram R; Arcturus Therapeutics, San Diego, CA, USA.
  • Limphong P; Arcturus Therapeutics, San Diego, CA, USA.
  • Tachikawa K; Arcturus Therapeutics, San Diego, CA, USA.
  • Karmali P; Arcturus Therapeutics, San Diego, CA, USA.
  • Payne J; Arcturus Therapeutics, San Diego, CA, USA.
  • Chivukula P; Arcturus Therapeutics, San Diego, CA, USA.
  • Ekim-Üstünel B; Institute for Diabetes and Cancer (IDC), Helmholtz Diabetes Center, Helmholtz Centre Munich, Neuherberg, Germany; Joint Heidelberg-IDC Translational Diabetes Program, Inner Medicine 1, Heidelberg University Hospital, Heidelberg, Germany; German Center for Diabetes Research (DZD), Neuherberg, Germany
  • Martinez-Jimenez CP; Helmholtz Pioneer Campus (HPC), Helmholtz Zentrum München, Neuherberg, Germany; TUM School of Medicine, Technical University of Munich, Munich, Germany.
  • Szendrödi J; Institute for Diabetes and Cancer (IDC), Helmholtz Diabetes Center, Helmholtz Centre Munich, Neuherberg, Germany; Joint Heidelberg-IDC Translational Diabetes Program, Inner Medicine 1, Heidelberg University Hospital, Heidelberg, Germany; German Center for Diabetes Research (DZD), Neuherberg, Germany
  • Nawroth P; Institute for Diabetes and Cancer (IDC), Helmholtz Diabetes Center, Helmholtz Centre Munich, Neuherberg, Germany; Joint Heidelberg-IDC Translational Diabetes Program, Inner Medicine 1, Heidelberg University Hospital, Heidelberg, Germany; German Center for Diabetes Research (DZD), Neuherberg, Germany
  • Herzig S; Institute for Diabetes and Cancer (IDC), Helmholtz Diabetes Center, Helmholtz Centre Munich, Neuherberg, Germany; Joint Heidelberg-IDC Translational Diabetes Program, Inner Medicine 1, Heidelberg University Hospital, Heidelberg, Germany; German Center for Diabetes Research (DZD), Neuherberg, Germany
Mol Metab ; 60: 101487, 2022 06.
Article in En | MEDLINE | ID: mdl-35378329
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Insulin Resistance / Diabetes Mellitus, Type 2 / Non-alcoholic Fatty Liver Disease Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Mol Metab Year: 2022 Type: Article Affiliation country: Germany
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Insulin Resistance / Diabetes Mellitus, Type 2 / Non-alcoholic Fatty Liver Disease Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Mol Metab Year: 2022 Type: Article Affiliation country: Germany